Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.38 USD | +5.38% | +2.18% | +24.75% |
Business Summary
Number of employees: 290
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100.0
%
| 5 | 100.0 % | 4 | 100.0 % | -15.28% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Australia
100.0
%
| 5 | 100.0 % | 4 | 100.0 % | -15.28% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stephen Betz
FOU | Founder | 58 | 01/08/01 |
Scott Struthers
FOU | Founder | 62 | 01/08/01 |
Marc Wilson
DFI | Director of Finance/CFO | 45 | 01/18/01 |
Dana Pizzuti
CTO | Chief Tech/Sci/R&D Officer | 69 | 30/22/30 |
Matt McDowell
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jeff Knight
COO | Chief Operating Officer | 53 | 30/21/30 |
Chris Robillard
PRN | Corporate Officer/Principal | - | 21/22/21 |
Garlan Adams
LAW | General Counsel | - | 16/21/16 |
Michael Monahan
LAW | General Counsel | - | 01/18/01 |
Brian Russell
PRN | Corporate Officer/Principal | - | 01/22/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Wendell Wierenga
CHM | Chairman | 76 | 01/15/01 |
Matthew Fust
BRD | Director/Board Member | 59 | 01/18/01 |
Director/Board Member | 71 | 03/20/03 | |
Caren Deardorf
BRD | Director/Board Member | 59 | 11/22/11 |
Director/Board Member | 60 | 03/22/03 | |
Weston Nichols
BRD | Director/Board Member | 39 | 01/18/01 |
Scott Struthers
FOU | Founder | 62 | 01/08/01 |
Stephanie Okey
BRD | Director/Board Member | 64 | 15/19/15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 78,744,364 | 74,939,799 ( 95.17 %) | 0 | 95.17 % |
Company contact information
Crinetics Pharmaceuticals, Inc.
6055 Lusk Boulevard
92121, San Diego
+858 450 6464
http://www.crinetics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.75% | 3.32B | |
+2.61% | 42.75B | |
+47.70% | 41.61B | |
+12.01% | 41.34B | |
-8.83% | 26.59B | |
+7.22% | 25.49B | |
-22.43% | 18.12B | |
+30.61% | 12.24B | |
-1.85% | 11.76B | |
+9.00% | 11B |
- Stock Market
- Equities
- CRNX Stock
- Company Crinetics Pharmaceuticals, Inc.